| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 3 |
| Mesenchymal stem cell therapy | 1 |
Target |
Mechanism COX-2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date31 Jan 1991 |
Target |
Mechanism PAI-1 inhibitors |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HSP90 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2028 |
Sponsor / Collaborator |
Start Date01 Apr 2027 |
Sponsor / Collaborator |
Start Date04 Dec 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
TM-5614 ( PAI-1 ) | Philadelphia chromosome positive chronic myelogenous leukemia More | Phase 1 |
Etodolac ( COX-2 ) | Multiple Myeloma More | Preclinical |
Glioblastoma (Kidswell Bio) | Glioblastoma More | Preclinical |
Luminespib ( HSP90 ) | stomach adenocarcinoma More | Preclinical |
ATF-HI-8 ( Trypsin x uPA ) | Neoplasms More | Discontinued |





